Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection

摘要

Abstract Several cohorts have shown that long‐term tenofovir‐containing combination antiretroviral therapy (cART) leads to higher HBsAg seroclearance rates in HIV/HBV coinfected patients vs HBV‐monoinfected patients under tenofovir disoproxil fumarate (TDF)‐based therapy. We have analysed data on determinants of HBsAg loss in a retrospective multicentric cohort of 359 HIV/HBV coinfected patients. Median CD4 T‐cell count at baseline was 359/ul (321‐404), CDC stage was C in 20% (n?=?70). Most patients (68%) were ART‐na?ve when TDF‐ or tenofovir alafenamide (TAF)‐containing cART was initiated (baseline). After a median follow‐up of 11?years HBsAg loss had occurred in 66/359 (18%) patients. However, patients with stage CDC C (P?≤?.001), lower CD4 gain (P?=?.043) and not receiving TDF/FTC (P?=?.008) were less likely to lose HBsAg. Long‐term TDF‐containing cART appears to achieve higher rates of HBsAg seroclearance compared to published data for HBV monoinfected subjects. However, late presentation for HIV and poor immune recovery significantly impair HBV seroconversion rates.